Solid-phase synthesis of [Ala1,3,11,15]-endothelin-1 by a modified double-coupling procedure

Area of Science:

• Peptide Chemistry
• Medicinal Chemistry
• Endocrinology

Background:

• Endothelin-1 (ET-1) is a potent vasoconstrictor peptide with a critical role in cardiovascular regulation.
• The disulfide bridges in ET-1 are essential for its biological activity and three-dimensional structure.
• Developing analogues of ET-1 can aid in understanding structure-activity relationships and potentially lead to new therapeutics.

Purpose of the Study:

• To synthesize a linear analogue of endothelin-1, specifically [Ala1,3,11,15]-Endothelin-1, by replacing the native cystine residues with alanine.
• To establish and optimize a solid-phase synthesis protocol for this linear analogue.
• To evaluate the yield and applicability of the developed method for producing other endothelin analogues.

Main Methods:

• Solid-phase peptide synthesis utilizing Fmoc (N-fluorenylmethoxycarbonyl) chemistry.
• An economical modified double-coupling procedure involving symmetrical anhydride followed by O-benzotriazolyl ester.
• Fully automated synthesis conditions with close monitoring of reaction parameters and purification.

Main Results:

• Successful synthesis of [Ala1,3,11,15]-Endothelin-1, a linear analogue of endothelin-1, was achieved.
• The synthesis yielded approximately 17% of the target peptide.
• The developed automated synthesis and purification conditions were found to be robust and potentially applicable to other endothelin analogues.

Conclusions:

• The study demonstrates the feasibility of synthesizing linear endothelin-1 analogues via automated solid-phase peptide synthesis.
• The modified double-coupling strategy offers an economical and efficient approach for peptide assembly.
• The established methodology provides a foundation for the synthesis of diverse endothelin analogues for further pharmacological investigation.